A Humanized Anti-VEGF Rabbit Monoclonal Antibody Inhibits Angiogenesis and Blocks Tumor Growth in Xenograft Models by Yu, Yanlan et al.
A Humanized Anti-VEGF Rabbit Monoclonal Antibody
Inhibits Angiogenesis and Blocks Tumor Growth in
Xenograft Models
Yanlan Yu
1., Pierre Lee
2., Yaohuang Ke
2., Yongke Zhang
2, Qiu Yu
2, Jonathan Lee
2, Mingzhen Li
3,
Jialiang Song
3, Jungang Chen
3, Jihong Dai
3, Fernando Jose Rebelo Do Couto
2, Zhiqiang An
2*, Weimin
Zhu
2, Guo-Liang Yu
2
1Department of Urology, Sir Run-Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, People’s Republic of China, 2Epitomics, Inc., Burlingame,
California, United States of America, 3Hangzhou Yikang Biotech, Inc., Hangzhou, People’s Republic of China
Abstract
Rabbit antibodies have been widely used in research and diagnostics due to their high antigen specificity and affinity. Though
these properties are also highly desirable for therapeutic applications, rabbit antibodies have remained untapped for human
disease therapy. To evaluate the therapeutic potential of rabbit monoclonal antibodies (RabMAbs), we generated a panel of
neutralizing RabMAbs against human vascular endothelial growth factor-A (VEGF). These neutralizing RabMAbs are specific to
VEGF and do not cross-react to other members of the VEGF protein family. Guided by sequence and lineage analysis of a panel
of neutralizing RabMAbs, we humanized the lead candidate by substituting non-critical residues with human residues within
both the frameworksand the CDR regions. We showed that the humanizedRabMAb retained its parental biological properties
and showed potent inhibition of the growth of H460 lung carcinoma and A673 rhabdomyosarcoma xenografts in mice. These
studies provide proof of principle for the feasibility of developing humanized RabMAbs as therapeutics.
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Introduction
Antibodies are becoming a major drug modality due to the high
specificity and affinity to their targets [1]. More than two dozen
therapeutic monoclonal antibodies are currently approved for the
treatment of cancer and other human diseases [1,2]. Most
therapeutic antibodies developed to date were either chimeric or
humanized murine antibodies due to early availability of the
mouse hybridoma technology [1,3]. Recently, transgenic mice and
in vitro phage display were employed to generate fully human
therapeutic antibodies [4,5,6,7]. These antibody platforms have
their own limitations; it is desirable to have access to other
antibody sources to increase the overall success rate of developing
more effective antibody therapies [8,9]. Rabbit has a robust
immune system to generate antibodies with high affinity and
specificity [10,11,12,13], but routine generation of rabbit mono-
clonal antibodies (RabMAbs) only become possible recently due to
the availability of a stable rabbit hybridoma fusion partner cell line
240E-W2 [14,15]. To evaluate rabbit antibodies for therapeutic
use, we generated a panel of neutralizing RabMAbs against
human vascular endothelial growth factor-A (VEGF), an angio-
genic growth factor [16,17]. Overexpression of VEGF correlates
with advanced tumor stage or tumor invasiveness in various types
of human cancers and blockage of VEGF/VEGFR-2 signaling is a
clinically proven strategy for the treatment of a number of cancers
[18,19]. We humanized a rabbit monoclonal antibody with high
affinity and specificity to VEGF using a unique strategy known as
mutational lineage guided (MLG) humanization [20,21]. Human-
ization of RabMAbs is an essential step in developing therapeutic
antibodies so as to minimize the potential human anti-rabbit
antibody response when administrated in humans [22]. We
demonstrate that the humanized anti-VEGF antibody retains the
parental affinities and biological activities. We also showed that
neutralizing VEGF signaling by the humanized RabMAb blocks
tumor growth and inhibits angiogenesis in two in vivo models. The
results described in this report demonstrate the potential for
developing humanized RabMAbs as therapeutics.
Results
Generation of Anti-Human VEGF RabMAbs
Six rabbits were immunized with full length human VEGF
fused to Fc domain of rabbit IgG recombinantly expressed in
mammalian cells. Two rabbits whose sera gave the best
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selected (data not shown). A total of 235 hybridomas with specific
binding to human VEGF were identified. Bevacizumab, a
humanized mouse anti-human VEGF antibody approved for
clinical treatment of colorectal cancer, and an anti-human Factor
VIII antibody were used as positive and negative controls,
respectively, in the VEGF/VEGFR-2 binding ELISA assay.
A panel of 15 anti-VEGF hybridoma antibodies that block
human VEGF binding to VEGFR-2 were identified from the 235
hybridomas with specific binding to human VEGF. The IC50 of
the 15 VEGF neutralizing antibodies ranged from 0.4 to 43 nM
when compared with Bevacizumab (IC50=0.9 nM) in the
receptor-ligand binding assay (Table 1). Titration and IC50
results of four representative anti-VEGF RAbMAbs (EBV311,
EBV312, EBV320, and EBV321) are shown in Figure 1A.W e
further evaluated the ability of these antibodies to block receptor
tyrosine phosphorylation triggered by VEGF binding [23].
HEK293 cells expressing full length VEGFR-2 were stimulated
with human VEGF in the presence or absence of VEGF
neutralizing antibodies. Figure 1B shows that all four represen-
tative anti-VEGF RabMAbs block receptor phosphorylation upon
VEGF stimulation.
All 15 VEGF neutralizing antibodies are highly specific to
human VEGF-A and they do not bind to human VEGF-B, -C,
and -D. Results for 7 representative antibodies are shown in
Figure 1C. To test cross-reactivity of the neutralizing antibodies,
mouse VEGF was included in the assay. Four of the 15 antibodies
bind to the human VEGF only and 11 of the antibodies are
human/mouse cross-reactive (Table 1 and Figure. 1C). As
expected, Bevacizumab is human VEGF specific.
Sequence and Structure Analysis of the VEGF
Neutralizing RabMAbs
Phylogenetic trees based on variable region amino acid
sequences of light (VK) and heavy (VH) chains of the 15 VEGF
neutralizing RabMAbs are shown in Figure 2A, B. Three of the 4
human VEGF specific antibodies (EBV301, EBV304, and
EBV308) are clustered in both the heavy and light chain lineages
(group 1 in Figure 2A, B). Similarly, six of the 11 cross-reactive
antibodies (EBV302, EBV307, EBV320, and EBV321 in group 2;
EBV303 and EBV313 in group 3) are also clustered in both the
heavy and light chain lineages (Figure 2A, B). The other cross-
reactive antibodies (EBV310, EBV311, EBV312, EBV322 and
EBV361) are dispersed within the large cluster where groups 2 and
3 are located in the light chain tree (Figure 2A). In the heavy
chain lineage tree, two cross-reactive antibody (EBV312 and
EBV361) is clustered with group 2 and another two (EBV311 and
EBV322) are clustered with group 3 (Figure 2B). Of the 30
sequences in the heavy and light chain lineage trees, there are only
two outliers. The human VEGF specific antibody EBV305 is
grouped with the cross-reactive antibodies (Figure 2A, B). The
heavy chain of cross-reactive antibody EBV310 is clustered with
group 1 which contains three human VEGF specific antibodies
(Figure 2B). To investigate the correlation between binding
activity and phylogenetic relationship, heavy and light chains of
the 15 antibodies were paired to generate 225 antibodies and their
binding activities to VEGF were determined (Table 2). Strong
structural activity relationship was observed. For example, the
heavy chain of clone EBV321 was able to pair with the light chains
of clones in the same lineage such as clones EBV302, EBV307 and
EBV320 (Group 2 in Figure 2A, B), but when paired with the
light chains of clones in different lineages it was not able to
reconstitute antigen binding activity (Table 2). Similarly, light
chain of clone EBV321 could pair with heavy chains from clones
in the same lineage group, EBV302, EBV307 and EBV 320, but
not with heavy chains from different lineage groups (Table 2).
The same was for antibodies in groups 1 and 3 (Figure 2A, B and
Table 2). Two exceptions were the heavy chains of EBV311 and
EBV322 which were able to pair with a number of light chains in
different lineage groups. However, their light chains could only
pair with their corresponding heavy chains (Table 2). Based on in
vitro biological activity, antigen binding affinity, and sequence
analysis, we selected EBV321 for humanization.
Table 1. In vitro characterization of anti-VEGF RabMAbs.
Clone name Inhibition of VEGF/VEGFR-2 interaction IC50 (nM)* Mouse VEGF crossreactivity
EBV301 0.991 6 0.086 2
EBV302 25.158 6 1.018 +
EBV303 1.023 6 0.079 +
EBV304 3.420 6 0.589 2
EBV305 5.182 6 0.556 2
EBV307 2.615 6 0.081 +
EBV308 1.835 6 0.081 2
EBV310 0.559 6 0.012 +
EBV311 42.999 6 6.210 +
EBV312 0.634 6 0.060 +
EBV313 1.243 6 0.040 +
EBV320 3.321 6 0.055 +
EBV321 0.560 6 0.026 +
EBV322 0.410 6 0.006 +
EBV361 1.818 6 0.361 +
Bevacizumab 0.893 6 0.044 2
*Mean 6 standard deviation of three replications.
doi:10.1371/journal.pone.0009072.t001
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PLoS ONE | www.plosone.org 2 February 2010 | Volume 5 | Issue 2 | e9072Figure 1. In vitro characterization of anti-VEGF RabMAbs. (A) Dose-dependent inhibition of VEGF/VEGFR-2 interaction by 4 representative
anti-VEGF RabMAbs. Bevacizumab and a non-relevant anti-human Factor VIII RabMAb were included as controls. Points represent means of three
replications and error bars represent standard deviations. The IC50 values are shown in the table below. (B) Inhibition of VEGF-stimulated receptor
tyrosine phosphorylation in 293/KDR cells in the presence of neutralizing antibodies against VEGF. Four representative anti-VEGF RabMAbs inhibited
VEGF stimulated VEGFR-2 phosphorylation in 293/KDR cells. Bevacizumab and a non-relevant anti-human Factor VIII RabMAb were used as positive
and negative controls, respectively. Total VEGFR-2 staining was performed as sample quantitative controls. (C) Specificity and cross-reactivity of anti-
VEGF RabMAbs. A panel of seven representative anti-human VEGF antibodies exhibited no reactivity to human VEGF-B, -C, -D. Four of the seven
antibodies (EBV302, EBV307, EBV320 and EBV321) were cross-reactive with mouse VEGF.
doi:10.1371/journal.pone.0009072.g001
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Antibody Engineering
The MLG method was used to humanize EBV321 into a human
IgG1 subclass with kappa light chain.First,the heavy (VH)andlight
chain (VK) variable region sequences of EBV321 were blasted
against the human germline VH and VK database [24]. The closest
human germline sequences, VH3-21/JH2 and VKI-A20/JK4 were
identified as the template for EBV321 humanization (Figure 2C,
D). Second, antibody sequences (EBV302, EBV307, and EBV320)
within the EBV321 lineage (group 2) were aligned (Figure 2A, B,
C, D). In the EBV321 lineage, the four clones have an identical VH
CDR3, share similar sequences in other CDRs, and contain the
same number of amino acid residues in the variable region
(Figure 2C, D). Third, the rabbit residues in the framework
regions potentially involvedinCDRcontacts orinter-chaincontacts
were identified based on the knowledge from human and mouse
antibodies. These residues, marked by ‘‘*’’, were not changed (28S,
48I, 49G, 70V, 74S, 79V,95F, 105P in VH and 22N, 43P in VK)
(Figure 2C, D) [25]. At CDR1 position 29 of VK, V is
interchangeable to L within the group and given that amino acids
I and L are structurally related, the original residue V in clone
EBV321 was changed to the human germline residue I at position
29 as marked by ‘‘#’’ (Figure 2D). Similarly, at CDR1 position 31
of VK, G is interchangeable to N within the group, so it was
mutated to the human germline residue N as marked by ‘‘#’’
(Figure 2D). Residues considered not critical to the structural
activity of the antibody as based on the phylogenetic analysis were
humanized as marked by ‘‘$’’ (72KRR and 83LRM of VH)
(Figure 2C). Residues at position 7T and 70Q of VK were
substituted with human germline residues S and D, respectively, as
marked by ‘‘ˆ’’ because they are facing solvent. In addition, the N-
terminal residues of VK (N’-LVRN’-DIQ) and VH (N’-QSRN’-
EVQ) were changed to match the human germline sequences. The
parental EBV321 antibodies before humanization were 69% and
Figure 2. Mutational lineage guided humanization of anti-VEGF RabMAb EBV321. (A–B) Phylogenetic analysis of VK (A) and VH (B) amino
acid sequences of 15 neutralizing anti-VEGF RabMAbs by Clustal X. The human antigen-specific clones are underlined. RabMAbs of the same lineage
group are boxed and labeled as 1, 2 or 3. (C–D) Alignments of VH (C) and VK (D) protein sequence of the EBV321 lineage group 2 (EBV302, EBV307,
EBV320 and EBV321) with human germline and humanized EBV321 sequences. ‘–’ denotes residues that are identical at the corresponding positions.
‘*’ denotes the residues in RabMAb framework regions potentially involved in CDR contacts or inter-chain contacts. ‘$’ denotes the residues
considered not critical to the structural activity. ‘#’ denotes the residues humanized in the CDR region. Chothia numbering scheme and Kabat CDR
loop definition were used [55,56].
doi:10.1371/journal.pone.0009072.g002
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frameworks. After MLG engineering, the frameworks of the final
humanized EBV321 (hEBV321) are 92% and 97% identical,
respectively, to the human germline VH and VK frameworks.
Epitope Mapping
A direct competition ELISA against human VEGF was
performed to determine whether the VEGF-A165 binding epitope
of hEBV321 is similar to that of Bevacizumab. The parental rabbit
EBV321 was used as a reference antibody. The binding of
EBV321 to VEGF was assessed in the presence of increasing
amount of hEBV321 or Bevacizumab competitor. Binding of
EBV321 to VEGF-A165 was not affected by hEBV321,
Bevacizumab or the negative control antibody Humira at low
concentrations (arrow A, Figure 3A). At 5 fold excess, hEBV321
inhibited the binding of EBV321 by 50% while Bevacizumab
showed very little competition (arrow B, Figure 3A). Further
increase in competitor concentration continued to reduce EBV321
binding and the binding of EBV321 was reduced to about 10%
and 37% by hEBV321 and Bevacizumab, respectively (arrow C,
Figure 3A). At intermediate concentration range, Bevacizumab
showed only partial competition with EBV321 as compared to
hEBV321 (Figure 3A), however EBV321 binding to VEGF was
abolished by either competitor at the highest concentration tested
(1000 fold excess). The control antibody Humira showed no
competition even at maximum concentration.
To further confirm that the epitope recognized by hEBV321 is
different from that of Bevacizumab, binding of hEBV321 to
mutated forms of VEGF A165 that affect Bevacizumab binding
were assessed. Binding of hEBV321 and Bevacizumab to the wild
type VEGF and VEGF-I46A were similar (Figures 3B and 3C).
Binding of hEBV321 to VEGF-G88A resembled its binding to the
wild type VEGF, but binding of Bevacizumab to VEGF-G88A
was substantially reduced as compared to hEBV321 (Figure 3D).
hEBV321 retained binding to VEGF G88A/Q89A at levels
comparable to wild type, but Bevacizumab binding was abolished,
reflecting distinct epitope binding (Figure 3E).
Biological Activities of the Humanized Anti-VEGF
RabMAb
To examine whether hEBV321 retains the properties of the
parental antibody, we first measured the antigen binding affinities
of hEBV321 and its parental EBV321 by surface plasmon
resonance (SPR); Bevacizumab was included in the same assay.
When VEGF was used as the analyte, the KDs of EBV321 and
hEBV321 were 419 pM and 11.5 pM, respectively (Table 3).
The KD for Bevacizumab was 16.6 nM (Table 3). Next, we
compared the blocking activity of hEBV321 and its parental
EBV321 in the ligand-receptor ELISA assay. hEBV321 blocked
the binding of human VEGF to human VEGFR-2 extracellular
domain with a similar dose-response curve and IC50 value as its
parental EBV321 (4.1 nM and 3.2 nM for EBV321 and
hEBV321, respectively) (Figure 4A). The ability of these two
antibodies to inhibit VEGF-induced receptor phosphorylation was
examined in a quantitative phospho-ELISA assay. The amount of
tyrosine phosphorylated receptors decreased with increasing
amount of hEBV321 and its parental RabMAb EBV321. We
further determined the activity of hEBV321 and EBV321 in
inhibiting VEGF-stimulated growth of HUVECs and results
showed that both clones displayed dose-dependent inhibition on
HUVEC growth (Figure 4B). RabMAb EBV321 exhibited
similar potency as Bevacizumab (IC50=0.039 nM vs. 0.048 nM),
whereas hEBV321 (IC50=0.008 nM) was about 5-fold and 6-fold
more potent than its parental RabMAb EBV321 and Bevacizu-
mab, respectively.
Efficacy of hEBV321 in the Human NCI-H460 Lung
Carcinoma and A673 Rhabdomyosarcoma Mouse
Xenograft Models
The in vivo efficacy of hEBV321 and its parental rabbit antibody
EBV321 were evaluated in two mouse xenograft models of human
cancers. In the first model, BALB/c nude mice were subcutane-
ously inoculated with NCI-H460 human lung cancer cells and
treatment began when established tumors reached an average size
Table 2. Antigen binding activity of random pairs of 15 anti-VEGF antibody H and L chains.
301L 302L 303L 304L 305L 307L 308L 310L 311L 312L 313L 320L 321L 322L 361L
301H ++ ––++ ––++ ––––––––
302H – ++ –––++ –––––++ ++ ––
303H – – ++ –––––––++ ––––
304H ++ ––++ ––++ ––––––––
305H ––––++ ––––––––––
307H – ++ –––++ – ++ –––++ ++ ––
308H ++ ––++ ––++ ––––––––
310H –––––++ – ++ ––––+ ––
311H ++ ++ – ++ – ++ – ++ ++ ––++ ++ ––
312H –––––––––++ –––––
313H – – ++ –––––––++ ––––
320H – ++ –––++ –––––++ ++ ––
321H – ++ –––++ –––+ – ++ ++ ––
322H – – ++ ––––+ ––++ ––++ –
361H ––––––––––––––++
The data were obtained from antigen binding ELISA with the antigen coated on a 96-well plate. ‘–’, antigen binding signal ,3X of background reading; ‘+’, antigen
binding signal between 3–106of background reading; ‘++’, antigen binding signal .106of background reading.
doi:10.1371/journal.pone.0009072.t002
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PLoS ONE | www.plosone.org 5 February 2010 | Volume 5 | Issue 2 | e9072Figure 3. Comparison of hEBV321 and Bevacizumab binding properties to human VEGF. A. VEGF competition ELISA measuring the
binding of hEBV321 to VEGF coated on ELISA plate in the presence of increasing concentration of competitor (hEBV321, Bevacizumab or an irrelevant
antibody Humira). B-E. Direct binding of hEBV321 and Bevacizumab to various forms of human VEGF captured on ELISA plate. B. VEGF wild type; C.
VEGF I46A; D. VEGF G89A; E. VEGF G88A/Q89A.
doi:10.1371/journal.pone.0009072.g003
VEGF hRabMAb in Tumor Models
PLoS ONE | www.plosone.org 6 February 2010 | Volume 5 | Issue 2 | e9072of about 100 mm
3. Antibodies were administered intraperitoneally
at 5 mg/kg/dose, 3 times per week for a total of 9 doses. All three
antibodies (hEBV321, EBV321 and Bevacizumab) showed
significant inhibition of tumor growth as compared to saline
control at dose of 5 mg/kg (hEBV321, P=0.0004; EBV321,
P=0.0015; Bevacizumab, P=0.042) (Figure 4C). After three
weeks of treatment, tumors were excised and measured. Tumor
growth inhibition [(C-T)/C%] by hEBV321 was 81.5% whereas
the Bevacizumab was 37.2% (P=0.003, hEBV321 vs. Bevacizu-
mab). At a lower dose (2.5 mg/kg), effective tumor growth
inhibition was also observed in hEBV321 treated mice (60%
inhibition, P=0.010), but not significant in the Bevacizumab
group (11% inhibition, P=0.567) (data not shown). Histological
examination of NCI-H460 tumor xenograft sections was per-
formed to determine the microvessel density. Tumor sections
stained with an antibody against vascular endothelial marker
CD34 revealed that treatment with 5 mg/kg of hEBV321,
EBV321, and Bevacizumab resulted in a weaker CD34 staining
and a lower density of CD34 positive blood vessels as compared to
saline treated control (P=0.0034, P=0.020, and P=0.040 vs.
control for hEBV321, EBV321, and Bevacizumab, respectively)
(Figure 4D, E).
In the A673 rhabdomyosarcoma xenograft model, antibodies
were administered intraperitoneally at 5 mg/kg/dose, 3 times per
week for a total of 9 doses. The animals were sacrificed when the
tumors reached 3000 mm
3 in size. The average tumor size in the
control group exceeded 3000 mm
3 after 5 doses (day 20 after
inoculation). Both antibodies showed significant inhibition of
tumor growth throughout the treatment (Figure 4F). The
inhibition of tumor growth by hEBV321 and Bevacizumab was
similar after 5 doses (79.6% and 72.5% respectively vs. control,
P,0.001). However, at the end of 3 weeks, average tumor size in
the hEBV321 and Bevacizumab treated groups were 1132 mm
3
and 1814 mm
3, respectively, and the difference between the two
treatments was statistically significant (P=0.019) (Figure 4F).
Discussion
In this study we have demonstrated the generation of highly
specific and potent neutralizing antibodies against human VEGF
using the rabbit monoclonal technology platform (RabMAbs). In
addition to their high affinity and specificity, RabMAbs exhibit
several other advantages [8,11,12,14,26]. First, due to the size of
the rabbit spleen, a larger pool of hybridomas can be generated
from fusion of a single immunized rabbit spleen. Second,
RabMAbs generally have higher affinity than mouse monoclonal
antibodies [9]. Higher binding affinity is one of the critical
parameters in selection of potent and efficacious therapeutic
antibodies [27,28,29]. Third, antibodies from rabbits are likely
cross-reacting with antigens from the mouse. In our anti-human
VEGF neutralization antibody panel, more than 50% of
RabMAbs, including EBV321, were cross-reactive to the mouse
VEGF. For therapeutic antibody development, a cross-reactive
antibody against the human and mouse targets provides a
convenient way to evaluate the antibody in mouse-based in vivo
efficacy models and eliminates the need for a surrogate antibody
during preclinical and animal toxicity studies. The lack of cross-
reactive antibodies has been an obstacle in preclinical develop-
ment of therapeutic antibodies [30,31]. In addition to cross-species
reactivity, rabbit antibodies are believed to recognize a greater
variety of epitopes than antibodies generated in mice [11,32], but
experimental data supporting this claim is lacking. The length of
CDR3 in the EBV321 light chain is 12 residues (Figure 2C, D)
which is longer than the average length of light chain CDR3 in
human or mouse IgGs [33]. The longer light chain CDR3 may
explain the higher diversity of rabbit antibody repertoires [34].
Finally, rabbit antibodies are more closely related to human than
mouse-derived antibodies [26].
Using the in vitro functional assay results and sequence analysis
data from a VEGF neutralizing RabMAb panel, we have
humanized clone EBV321 by selectively replacing the non-human
residues in both frameworks and a CDR (VK-CDR1). An
interesting feature was observed from the phylogenetic analysis.
The heavy chain phylogenetic tree overlaps with the light chain
phylogenetic tree suggesting that the heavy and light chains from
the same B-cell have co-evolved during B cell maturation. It
further suggested that antibodies in a lineage group are derived
from a single progenitor B cell. Such co-evolution of heavy and
light chains has been previously reported in vertebrates [35,36].
Further sequence analysis of antibodies within the same lineage
showed that both the frameworks and the CDRs are conserved
(Figure2C, D). The sequence variation among the antibodies in
the same lineage group are likely the result of somatic mutations of
the progenitor B cell. A lineage related antibody group defined by
sequence analysis was further confirmed by their cross reactivity to
human and murine antigens, and exchangeability of heavy and
light chains among the antibodies. While some of the mutations
contribute to antigen binding and structural stability, others are
not critical. For example, at position 72 of VH, R and K are
acceptable in lineage group 2 (Figure 2C); therefore, we
humanized the K residue in EBV321 to R. Another example is
position 31 of VK (CDR1) (Figure 2D) at which G and N are
interchangeable and we humanized the G residue in EBV321 to
N. Only one humanized version was tested and it retained the in
vivo and in vitro properties of the parental antibody, suggesting that
humanization guided by both biological and sequence information
allows for retention of full antibody activity. CDR grafting or
resurfacing based humanization methods rely primarily on
sequence information and by these methods it is difficult to
predict the role a specific residue plays in antibody activity [37,38].
As a result, multiple humanized versions are often tested in labor
intensive in vitro and in vivo assays [38,39]. Furthermore, unlike
other protocols, the MLG method allows for humanization of both
the framework and CDR regions.
hEBV321 demonstrated potent tumor inhibition in a NCI-
H460 human xenograft model. Although hEBV321 exerted a
more prominent inhibition on tumor growth and angiogenesis
than Bevacizumab when administered at the same dosage and
schedule, the higher potency of hEBV321 is likely in part due to its
recognition of the mouse VEGF. It has been reported that mouse
VEGF binds to human VEGFR-2 ECD in vitro [40]. Mouse VEGF
can also stimulate human HUVAC cell proliferation [41]. It has
also been reported that the existence of host-derived VEGF might
cause residual growth or drug resistance of human tumor
xenografts in nude mice treated with antibodies against human
Table 3. Binding affinities of anti-VEGF-A RabMAb EBV321
and its humanized version.
kon (1/Ms) koff (1/s) KD (M) x
2
EBV321-VEGF 2.85610
26 1.192610
23 4.19610
210 4.76
hEBV321-VEGF 1.63610
26 1.88610
25 1.15610
211 1.88
Bevacizumab 3.84610
24 5.78610
24 1.66610
28 0.90
kon, association rate constant; koff, dissociation rate constant; KD, equilibrium
constant; x
2, chi-squared distribution.
doi:10.1371/journal.pone.0009072.t003
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PLoS ONE | www.plosone.org 7 February 2010 | Volume 5 | Issue 2 | e9072Figure 4. Humanized EBV321 retains full biological activities in vitro and in vivo. (A) Comparison of hEBV321 and its parental RabMAb
EBV321 in the receptor-ligand interaction ELISA assay. Bevacizumab was included as a positive control. Points represent the means of three replicates
and error bars represent standard deviations. The IC50 values are shown in the table below. (B) Dose-dependent inhibition of HUVEC proliferation by
RabMAb EBV321, hEBV321, and Bevacizumab. Points represent the means of three replicates and error bars represent standard deviations. The IC50
values are shown in the table below. (C) Inhibition of tumor growth in vivo by anti-VEGF RabMAbs EBV321 and hEBV321 in NCI-H460 xenograft
model. Bevacizumab, EBV321, and hEBV321 were dosed at 5 mg/kg 3 times per week for a total of 9 doses (8 mice per group). Error bars represent
the standard deviation. (D) Photomicrographs of immunohistochemistry staining with an anti-CD34 mAb (x400). Representative areas of tumor
sections from cohorts receiving saline as control (i), Bevacizumab (ii), EBV321 (iii) and hEBV321 (iv). (E) MVD scoring of CD34 staining in NCI-H460
xenograft tumors. (F) Inhibition of tumor growth by hEBV321 in A673 xenograft model. Animals were i.p. injected with normal saline, 5 mg/kg
hEBV321 and Bevacizumab, 3 times per week for a total of 9 doses (8 to 11 mice per group). Symbols and bars, mean + standard deviation. Significant
difference when compared to the control group by ANOVA was denoted with *: P,0.05 or **: P,0.01. {, significant difference compared with the
bevacizumab group (P,0.05, student’s t test).
doi:10.1371/journal.pone.0009072.g004
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90% effective at inhibiting HM-7 and A673 xenograft growths in
nude mice, whereas its effectiveness drops below 50% in HPAC
tumors. This may be due to a higher level of host-derived VEGF
surrounding the tumor mass in the HPAC model than in the other
two models, and the fact that Bevacizumab only reacts with the
tumor-derived human VEGF [31]. The extent of contribution of
stroma-derived VEGF to NCI-H460 tumor growth has not been
reported. Therefore, in order to compare the in vivo efficacy of
blocking human tumor-derived VEGF, we further compared
hEBV321 and Bevacizumab in an A673 rhabdomyosarcoma
xenograft model, in which stromal VEGF is nearly non-existent
[31]. As was seen in the NCI-H460 model, hEBV321 showed
increased efficacy as compared to Bevacizumab in the A673
xenograft model, indicating that inhibition of stromal VEGF is not
necessary for the increased effectiveness of hEBV321.
Antagonists of VEGF signaling have been developed for anti-
angiogenic therapy, however, side effects have been observed
clinically, as is the case for Bevacizumab [43,44]. In vivo study
showed that hEBV321 inhibits tumor growth and angiogenesis
effectively at a dose as low as 0.25 mg/kg (data not shown). If this
translates into the clinical setting, hEBV321 may reduce the
unwanted side-effects associated with high dosage [45,46]. The
mechanismfor higher potencyofhEBV321 inthe preclinical models
is not clear, but at least three factors may contribute: higher affinity,
cross-reactivity to the mouse target, and recognition of a different
epitope. The affinity of hEBV321 is about 1444 fold higher than
Bevacizumab to VEGF (11.5 pM for hEBV321 vs. 16.6 nM for
Bevacizumab) (Table 3). The reported binding affinity of
Bevacizumab to VEGF was 2 nM [31]. The discrepancy between
thereported2 nMandour16.6 nMKdvalueforBevacizumabmay
be explained by the different formats used in the two experiments.
Liang et al. coupled the VEGF to the surface and used Bevacizumab
as the analyte [31]. The 2 nM Kd was a potential measurement of
avidity rather than affinity since IgG is bivalent.
VEGF blocking ELISA yielded similar IC50 values for EBV321
and hEBV321 (in the range of 3 to 4 nM; Figure 4A), whereas a 40
fold difference in SPR Kd values was observed for the two
antibodies (11.9 and 419 pM for hEBV321 and EBV321,
respectively; Table 3). This can be explained by the fundamental
difference between the two methods. While SPR such as Biacore
measures true Kd, solution IC50 determination by ELISA does not
measure true affinity constants for a given binding pair [47]. Based
on the definition of Kd, close to 100% of the binding partners exist
in the bound form once both partners are at a concentration 5–10
fold in excess of the Kd. Therefore, under the ELISA conditions in
which theantibody concentrations areinthe IC50range of 3–4 nM,
which represents ,100 fold and ,10 fold of Kd for hEBV321
(11.9 pM) and EBV321 (419 pM) respectively, all the antibodies
exist in the bound form, thus binding in this assay is more of a
stoichiometry driven event, rather then an affinity driven event.
The binding site on human VEGF to Bevacizumab and
VEGFR-2 have been examined previously [48,49,50]. Compet-
itive binding and mutagenesis studies suggest that hEBV321 and
Bevacizumab have partially overlapping epitopes, but with
different amino acid binding requirements. This is also supported
by the fact that hEBV321 cross-reacts to mouse VEGF while
Bevacizumab does not. The Bevacizumab VEGF binding profiles
are consistent with the previous report that VEGF residues G88
and G89, but not I46 are important binding determinants for
Bevacizumab [49,51]. The competitive ELISA results showed that
hEBV321competes for VEGF binding with the parental EBV321
in a dose responsive manner, suggesting that the humanization
process did not alter the antigen binding epitope.
In summary, we haveidentified a panel ofneutralizing RabMAbs
against human VEGF with high affinity and specificity. These
RabMAbs specifically block VEGF/VEGFR-2 interaction and
VEGF-induced receptor phosphorylation. In addition to binding
the human target, many of them can also recognize the mouse
ortholog. We have humanized one RabMAb and demonstrated
efficacyofthe humanized antibodyhEBV321 inneutralizingVEGF
functions both in vitro and in vivo. These results suggest that rabbit
monoclonal antibody technology combined with the MLG
humanization process represent a novel platform for efficiently
generating high quality candidates for therapeutic antibody
development. hEBV321 is currently in preclinical development.
Materials and Methods
Cell Lines and Proteins
Human umbilical vein endothelial cells (HUVECs) from Lonza
(Walkersville, MD) were maintained in Endothelial Basal Medi-
um-2 (EGMH-2, Lonza) supplemented with 2% fetal bovine serum
and growth factors (BulletKitH, Lonza). Cell line 293/KDR which
stably expresses human VEGFR-2 was purchased from SibTech,
Inc (Brookfield, CT). Other cell lines used in this report were
purchased from the American Type Culture Collection (Manassas,
VA). NCI-H460, 293/KDR, and A673 cells were maintained in
DMEM medium supplemented with 10% fetal bovine serum at
37uCi n5 %C O 2. The rabbit IgG Fc-hVEGF (human VEGF165)
and Fc-VEGFR-2 fusion protein expression constructs were
prepared by cloning human VEGF or VEGFR-2 extracellular
domain DNA fragments at the BglII and BamHI site C-terminal to
the rabbit IgG Fc in the mammalian expression plasmid vector
pTT5 (National Research Council, Canada). The recombinant
fusion proteins were expressed in transient transfected HEK293-
6E cells and purified from cell culture supernatant by Protein A
column chromatography. Recombinant human VEGF165 was
from Shanghai Primegene Bio-Tech Co. (Shanghai, China) and
R&D System (Mineapolis, MN). Other recombinant human
VEGF proteins (VEGF-B, VEGF-C, and VEGF-D) and mouse
VEGF were from R&D System.
Generation of Anti-Human VEGF RabMAbs
New Zealand white rabbits were immunized subcutaneously
with 0.2 mg recombinant Fc-hVEGF in TiterMax
TM Gold
Adjuvant (Sigma-Aldrich Corp., St. Louis, MO). After the initial
immunization, animals were boosted 3 times in a 3 week-interval.
Rabbits with the highest sera titers were intravenously boosted
with 0.4 mg immunogen four days before splenoectomy. Hybrid-
oma fusion was performed according to established protocol with
minor modifications [14]. Briefly, splenocytes were harvested from
the immunized rabbit and fused with rabbit plasmacytoma cells
240E-W2 [15] using PEG4000 (Sigma Chemical, St. Louis, MO)
and selected by HAT (hypoxanthine, aminopterin, and thymi-
dine). At end of the selection, hybridoma clones growing in the
original 96-well plates were transferred to new 96-well plates with
a medium change. Hybridoma supernatants were collected and
screened for antigen binding and neutralization of VEGF/
VEGFR-2 interaction. Hybridomas that were positive in the
binding and neutralization assays were subcloned, expanded and
frozen for future use.
Cloning and Expression of Recombinant RabMAbs
mRNAwas isolated from hybridoma cells and reverse-transcribed
to cDNA using the Qiagen TurboCapture mRNA kits (Qiagen, Inc,
Vaencia, CA). DNA fragments for the entire L chain and the
variable region of H chain (VH) of rabbit IgG were amplified by
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cloned into the pTT5 mammalian expression vector and the VH
fragment was fused in-frame to the constant region of H chain in
another pTT5 vector. For each hybridoma clone, three plasmid
DNA clones for H and L chains were sequenced and expressed as
recombinant RabMAbs for validation of cloning and subsequent
characterization. To express recombinant RabMAbs, the L and H
chain plasmids were co-transfected into 293-6E cells (National
Research Council, Canada) and supernatants were harvested 5 days
after transfection. The recombinant RabMAbs in the supernatants
were purified through protein A column, dialyzed in PBS buffer and
quantified at OD280 nm. For animal studies, the transiently
expressed recombinant RabMAbs were purified through Protein
A, HiTrap Phenyl HP and Hiprep 26/10 column (GE Healthcare
Bio-Sciences, Piscataway, NJ), quantified and filled into vials under
sterile condition. All data present in this paper were using
recombinant RabMAbs, unless it is specified otherwise.
VEGF/VEGFR-2 Interaction ELISA
A total of 5 mg/ml Fc-VEGFR-2 (ECD) fusion protein was
coated on ELISA plates at 4uC overnight and blocked in 1% BSA
in TBS containing 0.05% Tween-20 for 1 hour at room
temperature. Anti-VEGF RabMAbs, Bevacizumab (Roche, Basi-
lea, Switzerland) or control IgG were pre-incubated with
recombinant human VEGF (0.5 mg/ml final concentration) for
1 hour before transferring to the VEGFR-2-coated ELISA plates.
After 1 hour of incubation, the plates were washed with TBST
twice and VEGF bound to immobilized VEGFR-2 was detected
by a mouse anti-VEGF165 monoclonal antibody (Sigma-Aldrich
Corp., St. Louis, MO), followed by the addition of goat anti-mouse
IgG alkaline phosphatase conjugated antibody (Fisher Scientific/
Pierce Biotechnology, Rockford, IL). ELISA plates were developed
with p-nitrophenyl phosphate substrate and absorbance at 405 nm
was recorded. All experiments were performed in triplicates.
Endothelial Cell Proliferation Assay
HUVECs were seeded at a density of 4,000 cells/well in 96-well
plates. A total of 50 ml of the tested antibodies at indicated
concentrations were pre-incubated with 50 ml VEGF (15 ng/ml) for
1 hour before added to plates and incubated in EGMH-2 without
growth factor (assay medium) at 37uC, 5% CO2 for 72 hours. Then
10% AlamarBlueH (Serotec, Oxford, UK) was added to each well
and incubated for an additional 24 hours. Cell viability was
measured by a Wallac Victor V multilabel HTS counter
(PerkinElmer, Waltham, MA) with an excitation wavelength of
530 nm and emission wavelength of 590 nm. All studies were
conducted twice and in triplicates for each sample concentration.
Affinity Measurement of Anti-VEGF RabMAbs
Affinities were measured by BIAcore 3000 (BIAcore, Inc.,
Uppsala, Sweden). Antibodies were immobilized on CM5-
Sepharose chips coated by standard amine coupling chemistry to
a density of about 600 response units (RU) [52]. Measurements
were carried out at 25uC by injecting 250 ml of recombinant
VEGF165 (R&D Systems) at concentrations from 0.2 to 50 nM
with a flow rate of 35 ml/min. The dissociation duration for bound
analytes was 15 minutes in HBS-P running buffer (10 mM
HEPES, pH 7.4, 150 mm NaCl and 0.005% surfactant P20,
filtered and degassed). Data were analyzed with the BIAevaluation
software (version 3.2RC1) by applying a 1:1 binding model. The
obtained sensorgrams were fitted globally over the whole range of
injected concentrations and simultaneously over the association
and dissociation phases. Equilibrium dissociation constants were
then calculated from the rate constants (KD = koff/kon).
Inhibition of VEGF Stimulated VEGFR-2 Phosphorylation
The 293/KDR cells (1610
6 cells/well) were starved in DMEM
containing 0.2% fetal bovine serum for 4 hours. Anti-VEGF
RabMAbs were pre-mixed with 20 ng/ml human VEGF for
1 hour at room temperature. The antibody/antigen mixtures were
then added to the 293/KDR cells and incubated for 3 minutes at
37uC. After washing with cold PBS, the cells were lysed with cold
lysis buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl,
1 mM EDTA, 1% Triton X-100, 0.5 mM sodium orthovanadate,
1 mM phenylmethylsulfonyl fluoride, and complete protease
inhibitor mixture on ice (Cell Signaling, Danvers, MA). The
crude cell lysates were clarified by centrifugation and protein
concentration was determined by Bicinchoninic Acid Kit (Sigma-
Aldrich Corp., St. Louis, MO). The phosphorylation of VEGFR-2
on tyrosine residues were assessed by Western immunoblotting
and ECL detection using a mouse anti-phosphotyrosine PY99
monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz,
CA) and rabbit anti-VEGFR-2 polyclonal antibody (Epitomics
Inc., Burlingame, CA) as primary antibodies.
Mutational Lineage Guided (MLG) Humanization of
RabMAbs
A phylogenetic tree was built by alignment of VH and VL
amino acid sequences of selected RabMAbs. Sequence alignment
and phylogenetic analysis were performed using the ClustalX
software [53]. The parental RabMAb and the most closely related
human germline sequence were then aligned. Residues which are
known not to be structurally critical and/or subjected to change
during the in vivo maturation process were identified in the MLG
analysis and humanized. DNA encoding humanized VK and VH
were synthesized by MCLab (South San Francisco, CA, USA).
The human IgG signal peptide and a Kozak sequence were
engineered at the 59ends of the VK and VH sequences. The
humanized VK fragment was then cloned into human CK pTT5
vector at the HindIII and BsiWI site. Similarly, humanized VH
was cloned into a separate human IgG1 CH pTT5 vector at
HindIII and NheI site. Expression, purification and quantification
of the humanized RabMAbs are the same as those for
recombinant RabMAbs.
Direct Competion ELISA
ELISA microplate (Microlite 2, Thermo Scientific) was coated
with human VEGF-A165 (Shanghai PrimeGene Bio-Tech Co.,
Ltd.) in carbonate-bicarbonate buffer at 4uC overnight. The plate
was washed and blocked in 1%BSA TBST buffer. Bevacizumab,
hEBV321, or negative control antibody Humira were mixed
individually at increasing concentration with an equal volume of
hEBV321 (0.04 mg/ml). The antibody mixtures were then
transferred to the VEGF coated ELISA plate (0.05 mg/ml) and
incubated for 1 hr at room temperature. After washing, bound
hEBV321 was detected by peroxidase conjugated AffiniPure goat
anti-rabbit IgG and Fc fragment specific secondary antibody
(Jackson Immunoresearch, Cat. No. # 111-035-046). The ELISA
plate was then processed for ECL substrate development
(Femtoglow HRP Substrate Plus, Cat.# SHRPE21007, Michigan
Diagnostic LLC) and the chemiluminesence signal (RLU) was
recorded by Wallac Victor V (PerkinElmer, 1420 Multilabel HTS
Counter).
VEGF Mutants Cloning and Expression
Human VEGF-A 165 mutants I46A, G88A, and G88A/Q89A
were generated using QuikChange XL Site-Directed Mutagenesis
Kit (Stratagene, Catalog #200516) with human Fc-VEGF A 165
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manufacturer’s instructions. The mutagenic primers were synthe-
sized by Elim Biopharmaceuticals, Inc. and the mutations are
confirmed by DNA sequencing performed by MCLAB. The
primers used are: I46A forward - gatgagatcgagtacgccttcaagc-
catcctgtgtg; I46A reverse - cacacaggatggcttgaaggcgtactcgatctcatc;
G88A forward - caaacctcaccaagcccagcacataggagag; G88A reverse
- ctctcctatgtgctgggcttggtgaggtttg; G99A/Q89A forward - cggat-
caaacctcaccaagccgcccacataggagagatg; and G99A/Q89A reverse -
catctctcctatgtgggcggcttggtgaggtttgatccg.
The wild type and mutant VEGF-A-Fc-fusion proteins were
expressed by transient transfection of HEK-293E cells. Two
independent clones for each mutant were expressed and analyzed.
Briefly, HEK-293 cells were plated in 2 ml of freestyle 293
expression medium (Invitrogen, Cat. No. 12338) in 6-well tissue
culture plates and transfected with various DNA complexed with
293fectin Transfectin Reagent in OptiMEM Complexing Medium
(Invitrogen, Cat. Nos. 12347-019 and 31985-070). The culture
medium was supplemented with TN1 peptone 24 hrs post-
transfection and harvested on day 5. The culture media were
centrifuged at 1200 g for 5 min. The cleared supernatants were
used for VEGF capture ELISA binding experiment.
VEGF Capture ELISA Binding Assay
ELISA microplates (Microlon, high binding, Greiner Bio-One,
Cat. No. # 650061) were coated with AffiniPure goat anti-rabbit
IgG (H+L) (Jackson ImmunoResearch, Cat. No. 111-005-003) in
0.05M carbonate-bicarbonate buffer at 4uC overnight. The plates
were then blocked in 1% BSA in TBST for 2 hr at 37uC. Fc-
VEGF protein supernatants were added to the well and incubated
for 1 hr at 37uC. The plates were washed in TBST before addition
of anti-VEGF antibodies (hEBV321 or Bevacizumab) at various
concentrations for 1 hr at 37uC. This was followed by washing and
incubation at 37uC with alkaline phosphatase conjugated goat
anti-human IgG (H+L) secondary antibody (Pierce/Thermo
Scientific, Cat. No. 31310). After washing in TBST, the ELISA
plates were developed by addition of p-nitrophenyl phosphate
solution at room temperature. The reaction was stopped by
addition of NaOH and the plates were read at 405 nm with an
ELISA plate reader (Labsystems Multiskan Ascent Photometric
plate reader).
Establishment and Treatment of Human Tumor
Xenografts in BALB/c Nude Mice
NCI-H460 or A673 cells were maintained in DMEM/10%FBS
medium until 80% confluence. Female BALB/c nu/nu mice 6–8
weeks of age were obtained from Shanghai SLAC Laboratory
Animal Co. Ltd. (Shanghai, China). The mice were housed at
five/cage in microisolator units under humidity- and temperature-
controlled conditions with 12-hour light/dark cycle, and fed with a
standard sterile laboratory diet (Zhejiang Chinese Medical
University, Hangzhou, China). Xenografts were established by
subcutaneous injection of 1610
7 cells/mouse into the dorsal
flanks. When tumors reached an average volume of about
100 mm
3 (50,200 mm
3), the animals were randomized into
groups. Antibodies were administered intraperitoneally at 5 mg/
kg per dose or as indicated. The control group received sterile
saline. Dosing was administered 3 times per week for a total of 9
doses. Tumor size and body weight were recorded every 2 to 3
days. Perpendicular dimensions of the tumor were measured using
a Vernier scale caliper. Tumor volumes were calculated according
to the following equation: Volume = (width)
2 6 length/2.
Animals were euthanized three weeks after the first treatment and
tumors were removed and weighed. All procedures were
conducted in accordance to Animal Care and Use Committee
guidelines of Zhejiang Chinese Medical University.
To assess tumor histology and microvessel density (MVD),
MVD scores of tumor xenografts were determined by quantifying
immunohistochemical staining of the CD34 marker using a
modified method described previously [54]. Briefly, tissue sections
were processed, deparaffinized, rehydrated, and quenched for
endogenous peroxidase activity. Murine vessels in tumor xeno-
grafts were immunostained with rabbit anti-mouse CD34 antibody
(Zhongshan Goldenbridge Biotechology Co., LTD., Beijing,
China) for 1.5 hours at 37uC. After washing with PBS three
times, sections were incubated with goat anti-rabbit IgG-
horseradish peroxidase for 30 minutes. The slides were developed
with diaminobenzidine (DAB) and counterstained with Haema-
toxylin. The entire tumor section was scanned under a light
microscope at low power magnification (6100) to identify ‘‘hot
spots’’, which are the areas of the highest neovascularization.
Individual microvessels were then counted under a high power
(6400) field to obtain a vessel count in a defined area, and the
average vessel count in five hot spots was taken as the MVD.
Statistical Analysis
Results are expressed as mean 6 standard deviation, unless
otherwise indicated. Data and graphs were analyzed with
Graphpad Prism software (Graphpad Software Inc., La Jola,
CA). Statistical significance of multiple comparisons was deter-
mined by ANOVA and difference between two groups was
determined by two-tailed Student’s t test. A p-value of ,0.05 was
taken as statistically significant.
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